To test our hypothesis that increased CD8 cells in our product would improve efficacy of Luc90-CAR-T, we compared survival and tumor burden of mice treated with Luc90-CAR-T or ΔCS1-Luc90-CAR-T using our high tumor burden MM.1S-CG mouse model, as above. Here, CD8A is linked to neoplasm.